MYC and neoplasm: To evaluate if the drug resistance of RAD001 observed in QGP-1/shPTEN/LKB1 cells can be reversed by the addition of metformin or a c-Myc inhibitor in vivo, we treated the mice inoculated with QGP-1/shLuc and QGP-1/shPTEN/LKB1 cells with RAD001 alone, metformin alone, 10058-F4 alone, RAD001 + metformin or RAD001+ 10058-F4 for 2 weeks (5 days treatment and 2 days rest per week) and observed tumor growth.